http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Guo-Ling Li,Li-Fang Zhang,Zhong-Hai Ni,Hui-Zhong Kou,Ai-Li Cui 대한화학회 2012 Bulletin of the Korean Chemical Society Vol.33 No.5
Three new cyanide-bridged CrIIIMnII binuclear complexes, [Mn(phen)2Cl][Cr(bpmb)(CN)2]·H2O (1) (phen = 1,10-phenanthroline, bpmb2– = 1,2-bis(pyridine-2-carboxamido)-4-methyl-benzenate), [Mn(phen)2Cl][Cr(bpdmb)- (CN)2]·H2O (2) (bpdmb2– = 1,2-bis(pyridine-2-carboxamido)-4,5-dimethyl-benzenate), and [Mn(phen)2Cl]- [Cr(bpClb)(CN)2]·CH3OH·H2O (3) (bpClb2– = 1,2-bis(pyridine-2-carboxamido)-4-chloro-benzenate) were obtained based on Mn(phen)2Cl2 and a series of dicyanidechromate(III) building blocks. Single crystal X-ray diffraction analysis shows the structures of the three complexes are dimeric type with two different metal centers linked by a cyanide group from corresponding dicyanidechromate(III) building block. Magnetic investigations indicate the existence of relatively weak antiferromagnetic coupling between Cr(III) and Mn(II) ions with best-fit constants JCrMn = –2.78(5) cm–1 for 1, JCrMn = –3.02(2) cm–1 for 2 and JCrMn = –2.27(3) cm–1 for 3 based on the spin exchange Hamiltonian = –2JCrMn Cr Mn. The magneto-structural correlation of cyanide-bridged CrIIIMnII complexes has been discussed at last.
Li, Guo-Ling,Zhang, Li-Fang,Ni, Zhong-Hai,Kou, Hui-Zhong,Cui, Ai-Li Korean Chemical Society 2012 Bulletin of the Korean Chemical Society Vol.33 No.5
Three new cyanide-bridged $Cr^{III}Mn^{II}$ binuclear complexes, $[Mn(phen)_2Cl][Cr(bpmb)(CN)_2]{\cdot}H_2O$ ($\mathbf{1}$) (phen = 1,10-phenanthroline, $bpdmb^{2-}$ = 1,2-bis(pyridine-2-carboxamido)-4-methyl-benzenate), $[Mn(phen)_2Cl][Cr(bpmb)-(CN)_2]{\cdot}H_2O$ ($\mathbf{2}$) ($bpdmb^{2-}$ = 1,2-bis(pyridine-2-carboxamido)-4,5-dimethyl-benzenate), and $[Mn(phen)_2Cl]-[Cr(bpClb)(CN)_2]{\cdot}CH_3OH{\cdot}H_2O$ ($\mathbf{3}$) ($bpClb^{2-}$ = 1,2-bis(pyridine-2-carboxamido)-4-chloro-benzenate) were obtained based on $Mn(phen)_2Cl_2$ and a series of dicyanidechromate(III) building blocks. Single crystal X-ray diffraction analysis shows the structures of the three complexes are dimeric type with two different metal centers linked by a cyanide group from corresponding dicyanidechromate(III) building block. Magnetic investigations indicate the existence of relatively weak antiferromagnetic coupling between Cr(III) and Mn(II) ions with best-fit constants $J_{CrMn}=-2.78(5)cm^{-1}$ for $\mathbf{1}$, $J_{CrMn}=-3.02(2)cm^{-1}$ for $\mathbf{2}$ and $J_{CrMn}=-2.27(3)cm^{-1}$ for $\mathbf{3}$ based on the spin exchange Hamiltonian = $-2J_{CrMn}\hat{S}_{Cr}\hat{S}_{Mn}$. The magneto-structural correlation of cyanide-bridged $Cr^{III}Mn^{II}$ complexes has been discussed at last.
Ran Zhang,Zhong-Hai Ni,Li-Fang Zhang,Hui-Zhong Kou 대한화학회 2014 Bulletin of the Korean Chemical Society Vol.35 No.7
A new tetranuclear Mn(III) complex [MnIII 4(sae)4(μ3-O)(μ1,1-N3)(OH)(H2O)2]·H2O (1) (H2sae = 2-salicylideneamino- 1-ethanol) has been synthesized by the reaction of MnCl2·4H2O, H2sae and sodium azide in the mixed solvent of methanol, acetonitrile and water. The X-ray diffraction analysis shows that the four Mn(III) ions in complex 1 have a unique adamantine arrangement, whereas the coordination environment of each Mn(III) ions is different. Magnetic studies indicate that complex 1 manifests antiferromagnetic behaviors. The magnetic susceptibilities of complex 1 have been fitted by two magnetic models based on the suitable analysis of its magnetic structural topology.
Zhang, Ran,Ni, Zhong-Hai,Zhang, Li-Fang,Kou, Hui-Zhong Korean Chemical Society 2014 Bulletin of the Korean Chemical Society Vol.35 No.7
A new tetranuclear Mn(III) complex $[Mn^{III}{_4}(sae)_4({\mu}_3-O)({\mu}_{1,1}-N_3)(OH)(H_2O)_2]{\cdot}H_2O$ (1) ($H_2sae$ = 2-salicylideneamino-1-ethanol) has been synthesized by the reaction of $MnCl_2{\cdot}4H_2O$, $H_2sae$ and sodium azide in the mixed solvent of methanol, acetonitrile and water. The X-ray diffraction analysis shows that the four Mn(III) ions in complex 1 have a unique adamantine arrangement, whereas the coordination environment of each Mn(III) ions is different. Magnetic studies indicate that complex 1 manifests antiferromagnetic behaviors. The magnetic susceptibilities of complex 1 have been fitted by two magnetic models based on the suitable analysis of its magnetic structural topology.
Development and characterization of a fully functional small anti-HER2 antibody
( Jie Gao ),( Bo Hua Le ),( Hui Mei Li ),( Xun Min Zhang ),( Da Peng Zhang ),( Lei Zhao ),( Chong Wang ),( Chen Fang ),( Wei Zhu Qian ),( Sheng Hou ),( Geng Kou ),( Hua Feng Wei ),( Shu Shi ),( Hao Wa 생화학분자생물학회 2009 BMB Reports Vol.42 No.10
Jingui Hu,Ling Zhang,Fei Fu,Qiong Lai,Lu Zhang,Tao Liu,Boyang Yu,Junping Kou,Fang Li 고려인삼학회 2022 Journal of Ginseng Research Vol.46 No.2
Background: Ginsenoside Rb1, a bioactive component isolated from the Panax ginseng, acts as a remedy to prevent myocardial injury. However, it is obscure whether the cardioprotective functions of Rb1 are related to the regulation of endogenous metabolites, and its potential molecular mechanism still needs further clarification, especially from a comprehensive metabolomics profiling perspective. Methods: The mice model of acute myocardial ischemia (AMI) and oxygen glucose deprivation (OGD)-induced cardiomyocytes injury were applied to explore the protective effect and mechanism of Rb1. Meanwhile, the comprehensive metabolomics profiling was conducted by high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry (HPLC-Q/TOF-MS) and a tandem liquid chromatography and mass spectrometry (LC-MS). Results: Rb1 treatment profoundly reduced the infarct size and attenuated myocardial injury. The metabolic network map of 65 differential endogenous metabolites was constructed and provided a new inspiration for the treatment of AMI by Rb1, which was mainly associated with mitophagy. In vivo and in vitro experiments, Rb1 was found to improve mitochondrial morphology, mitochondrial function and promote mitophagy. Interestingly, the mitophagy inhibitor partly attenuated the cardioprotective effect of Rb1. Additionally, Rb1 markedly facilitated the phosphorylation of AMP-activated protein kinase a (AMPKa), and AMPK inhibition partially weakened the role of Rb1 in promoting mitophagy. Conclusions: Ginsenoside Rb1 protects acute myocardial ischemia injury through promoting mitophagy via AMPKa phosphorylation, which might lay the foundation for the further application of Rb1 in cardiovascular diseases.
( Chen Wang Chang ),( Shu Chen Wei ),( Jen Wei Chou ),( Tzu Chi Hsu ),( Chiao Hsiung Chuang ),( Ching Pin Lin ),( Wen Hung Hsu ),( Hsu Heng Yen ),( Jen Kou Lin ),( Yi Jen Fang ),( Horng Yuan Wang ),( 대한장연구학회 2014 Intestinal Research Vol.12 No.4
Background/Aims: Only moderate to severe Crohn`s Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Japan and Korea. We aim to explore the efficacy of using adalimumab in CD patients under such stringent criteria. Methods: A retrospective analysis was conducted in nine medical centers in Taiwan and we collected the results of CD patients receiving adalimumab from Sep 2009 to Mar 2014. The clinical characteristics, response measured by CDAI (Crohn`s Disease Activity Index), adverse events and survival status were recorded and analyzed. CR-70, CR-100, and CR-150 were defined as attaining a CDAI decrease of 70, 100 or 150 points compared with baseline. Results: A total of 103 CD patient records were used in this study. Sixty percent of these patients received combination therapy of adalimumab together with immunomodulators. CR-70 was 68.7%, 74.5% and 88.4% after week 4, 8 and 12 of treatment, respectively. The steroid-free rate, complications and survival were 47.6%, 9.7% and 99% of patients, respectively. In considering the mucosal healing, only 25% patients achieve mucosal healing after treatment for 6 to12 months. Surgery was still needed in 16.5% of patients. Combination treatment of adalimumab with immunomodulators further decreased the level of CDAI at week 8 when compared with the monotherapy. Conclusions: Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria. (Intest Res 2014;12:287-292)